Customer Brand Preference Plan

Smart Pharma Consulting How to build a *SMART* Customer Brand Preference Plan?

Position Paper

February 2016

1, rue Houdart de Lamotte – 75015 Paris – France Tel.: +33 6 11 96 33 78 – Fax: +33 1 45 57 46 59 E-mail: jmpeny@smart-pharma.com Website: www.smart-pharma.com In many cases, Brand Plans are inefficient and of little use due to a weak building process, a lack of market insight and an insufficient involvement of brand teams

Why current "Brand Plans" are of limited use?

- Based on their solid experience, Smart Pharma consultants have observed the following key facts:
 - 1. At affiliate level, the Brand Plan process is often viewed as a constraint and as not essential
 - 2. Therefore, **brand teams minimize** the **time spent** to prepare their plan
 - 3. In spite of a large quantity of available data, the **knowledge** and the **understanding** of key market **stakeholders** are often **insufficient** and **not accurate**
 - 4. Strategic priorities are not always driven from the market situation analysis and not always supported by the corresponding operational activities
 - 5. Most of the brand plans do not include relevant monitoring tools and a monitoring process

Pharma companies should abandon their current Brand Plan process which is of limited use... ... and drastically transform it into an effective and efficient strategic tool for its affiliates

The "Customer Brand Preference Plan" and its corresponding building process and tools proposed by Smart Pharma Consulting are a "Must-Have" for brand teams

Why building "Customer Brand Preference Plans"?

- Smart Pharma consultants have capitalized on:
 - 24 years of Strategy & Marketing consulting in the pharma industry¹ and
 - 25 years of teaching in the top European B-schools (e.g. HEC, ESSEC, ESCP Europe, etc.)

to elaborate the **principles of a robust "Customer Brand Preference Plan**" which will contribute better than conventional "Brand Plans" and even better than "Customer-focused Brand Plans" to **optimize** the **brands performance**

- If properly built:
 - Through a rigorous strategic and tactical thinking process
 - Following a robust but simple methodology
 - Using practical tools

the "Customer Brand Preference Plans" will help brand teams develop a "Must-Have" plan

 The "Customer Brand Preference Plan" should reinforce the strategic and tactical thinking, lead to a more efficient and effective resource allocation to meet the objectives set for the brand

3

To help brand teams adopt the highly effective "Customer Brand Preference Plan", Smart Pharma Consulting suggests a set of principles, methods and tools

How to build "Customer Brand Preference Plans"?

- To help brand teams build an **efficient brand plan**, Smart Pharma Consulting proposes to:
 - Apply the concept of "customer-preference" which is the most relevant driver to optimize the brand market share
 - Design a "Customer Brand Preference Plan" which allows to apply this concept
 - Adopt the 4Ws (What? Why? so What? What to do?) approach which ensures a better consistency between the market situation analysis and the selected actions to be implemented
 - Replace the conventional SWOT by the Advanced SWOT which is more analytical and thus facilitates the identification of strategic priorities
 - Draw the "Customer Brand Preference Card" which summarizes: the brand ambition in terms
 of performance, the strategic preference drivers per customer segment to meet this ambition
 and the tactics which will support each strategic driver
 - Select Key Execution Indicators (KEIs) to monitor following a predefined process the quality of execution of the actions and Key Performance Indicators (KPIs) to measure their impact

A Smart Pharma Consulting

The Brand Preference Mix is a framework that can be used to create a superior customers preference and to ensure maximum market shares



Brand Preference Mix (1/2)

- As the great majority of prescribers use several brands for a given pathology:
 - The challenge for pharma companies is to increase the preference of prescribers for their brands, to gain a greater share of their prescriptions (vs. competitors)
 - Strengthening the preference of a prescriber for a brand must go beyond only securing the loyalty to the brand
- To reinforce brand preference, pharma companies should optimize their Brand Preference Mix:
 - The perceived value of their brand (product) attributes
 - The perceived quality of the services they offer and deliver to physicians
 - Their corporate reputation
- The links between the three components of the Brand Preference Mix should be well established in the mind of prescribers

Sources: "Building prescriber loyalty", J.-M. Peny et al., SCRIP Magazine, September 1993 – Smart Pharma Consulting analysis

To boost the preference of physicians for their brands, pharmaceutical companies can leverage the three components of their Brand Preference Mix



Source: Smart Pharma Consulting analysis

¹ Physicians, patients, pharmacists, nurses, payers, health authorities, etc.

The Brand Preference Mix Index enables to assess the brand performance on each of the preference components, over time and compared with competitors



Brand Preference Mix Index

- The Brand Preference Mix Index (BPM Index) measures:
 - The relative importance of the three BPM components per brand
 - The score of the brand, on a 10-point scale, for each of its preference components
- The BPM Index can be defined per customer¹, per indication, per form, etc.
- The BPM Index reflects the customer perception at a given point in time, making possible to track the evolution of this perception over time and to compare it with competitors, considering:
 - External events (i.e. related to health authorities, competitors and customers behaviors)

February 2016

Internal events (i.e. related to promotional activities, quality of services offered, new communication strategy, etc.)

Source: Smart Pharma Consulting analysis

¹ Distributors, nurses, patients, payers, patients advocacy groups, pharmacists, physicians, etc.. The BPM Index could be also used for other stakeholders such as: health authorities, journalists, activists, etc..

The strategic & tactical thinking process aims to align strategy with market key success factors and identify critical challenges related to the brand



The Strategic & Tactical Thinking Process (1/2)

Source: Smart Pharma Consulting analysis

¹ Distributors, nurses, patients, payers, patients advocacy groups, pharmacists, physicians, etc. – ² Accounts for indications, clinical evidence and positioning, etc. – ³ Accounts for price, reimbursement and hospital listing

Customer Brand Preference Plan – The Smart Pharma Way

February 2016

To be efficient, Customer Brand Preference strategies should be supported by an appropriate thinking process, including customer insights and an adequate monitoring



9

Source: Smart Pharma Consulting analysis

¹ Including companies activities, processes, structure and culture – ² Key Performance Indicators – ³ Key Execution Indicators

The 4 Ws approach enables brand teams to make evidence-based decisions and therefore to improve their relevance and their robustness

The 4 Ws approach

WHAT?	WHY?	SO WHAT?	WHAT TO DO?
 Identify key market facts and events: Sales data (competitors and own sales) Opinion, decisions and / or behavioral changes of key stakeholders (e.g. health authorities, competitors and customers¹ and the company itself) 	 Understand the factors that have triggered or that are likely to trigger market facts and events: What are the root causes of sales data and trends? What are the root causes of health authorities, competitors and customers¹ opinion, decisions and / or behavior? Etc. 	 Analyze the implications for the stakeholders (e.g. health authorities, competitors, customers¹ and the company itself) related to the key market facts and events that have been identified or anticipated Define if these facts and events represent opportunities or threats for the company (and its brands) 	 Based on the three previous steps (WHAT – WHY – SO WHAT) define the relevant strategic and tactical decisions to be made to optimize the brand performance These strategic and tactical decisions should contribute to reinforce the three components² of the Brand Preference Mix (BPM)

Source: Smart Pharma Consulting analysis

¹ Distributors, nurses, patients, payers, patients advocacy groups, pharmacists, physicians, etc.. – ² Brand attributes, service quality and corporate reputation perception by customers The situation analysis should focus on identifying and analyzing current and future key market events from which implications for the brand will be deducted

Situation analysis

2 Pagulatory & Market Access



4. Competitors Assessment

	Overall Position	Strengths Weaknesses (What?)	Rationale (Why?)	Implications (So What?)
Brand	+			
Competitor 1	+++			
Competitor 2	+			
Competitor 3	++			

2. Regulatory & Market Access											
	Trends	Description (What?) Analysis (Why?)	Implications (So What?)								
Registration conditions	-										
Pricing / Reimbursement policy	=										
Medical guidelines	+										
Public Health initiatives	NA										

5. Evaluation of brand recent tactics

Targeted customer	Objective	Tactic/Action (What?)	Cost (K€)	Results vs. objectives	Rationale (Why?)	Implications (So What?)
						Continue
						Reconsider
						Abandon
						Increase

3. Customer Opinion & Behavior

Customer segments	Trends	Description (What?) Analysis (Why?)	Implications (So What?)
Customers #1	=		
Customers #2	++		
Customers #3	-		

6. Evolution of the Market Environment



Source: Smart Pharma Consulting analysis

The "Advanced SWOT" helps brand teams carry out a more specific and relevant assessment of the market situation and of the brand competitive position

Advanced SWOT (1/3)



Source: Smart Pharma Consulting analysis

Brand teams should identify and prioritize market opportunities and threats according to their importance in driving brand performance

Advanced SWOT (2/3) -

Opportunities	Relative importance ¹	Threats	Relative importance ¹
What might positively impact market dynamics?		What might negatively impact market dynamics?	
Authorities: new indications, guidelines, etc.		 Authorities: guidelines tightened, usage restriction imposed, price decrease, de- 	
 Customers: prescriptions behaviors (e.g. off- label), emergence of new prescribers, 		reimbursement, market withdrawals, etc.	
improvement of patients adherence, etc.		 Customers: prescriptions behaviors (e.g. preference for generics), etc. 	
 Competition: withdrawal of some competitors, decrease in promotional investments, patent expiry, etc. 		 Competition: generics threat, new market players, increase in promotional investments, etc. 	

Performance d	lrivers ((illustr	ative)

- 1. Set competitive price
- 2. Prove superior efficacy
- 3. Obtain support from KOLs
- 4. Run relevant clinical studies
- 5. Benefit from a strong corporate reputation
- 6. Offer service quality

Items on which brands need to perform better to gain market shares and / or increase the market size

Source: Smart Pharma Consulting analysis

¹ Rating from 5: very high importance to 1: very limited importance

Brand teams should identify and prioritize their brand's strengths and weaknesses to effectively define key challenges expected over the projected period

Advanced SWOT (3/3)

Strengths	Relative importance ¹	Weaknesses	Relative importance ¹
What are / will be the brand advantages?		What are / will be the brand disadvantages?	
 Corporate reputation: size, reactivity, efficiency, skills, expertise, innovation, access to medicine, etc. 		• Corporate reputation: size, reactivity, efficiency, skills, expertise, innovation, access to medicine, etc.	
 Service quality: value of services, usefulness, quantity, quality of execution, etc. 		 Service quality: value of services, usefulness, quantity, quality of execution, etc. 	
 Brand perception: Attributes: indications, formulations, patent, etc. Price: price level, reimbursement status, etc. Distribution: direct / indirect, rebating strategy, etc. Promotion: marketing / medical investment, etc. 		 Brand perception: Attributes: indications, formulations, patent, etc. Price: price level, reimbursement status, etc. Distribution: direct / indirect, rebating strategy, etc. Promotion: marketing / medical investment 	

Brand challenges / Critical issues (illustrative)

- 1. Obtain new indication XYZ
- 2. Defend brand reimbursement status
- 3. Improve brand presence among the targeted physicians
- 4. Strengthen the corporate reputation
- 5. Improve perceived quality of services to physicians

Source: Smart Pharma Consulting analysis

¹ Rating from 5: very high importance to 1: very limited importance

It is key to make sure that existing or planned activities will significantly contribute to reinforce the preference of the brand with the help of specific tools



15

Brand Ambition

Source: Smart Pharma Consulting analysis

¹ Base case, i.e. the most probable scenario – ² Compounded annual growth rate

The Customer Brand Preference Card is a useful tool to align the brand ambition, the strategic preference drivers by customer segment and the corresponding tactics¹



Source: Smart Pharma Consulting analysis

¹ Strategic preference drivers will be defined by customer segment and supported by a combination of coordinated tactics

16

Before deciding to implement any action; objectives, target customers and expected impact should be clearly defined, as well as execution and performance indicators

Monitoring Tools: KPIs¹ & KEIs²

		Action	
What is the objective of the action?	2 Who are the targeted customers?	3 What are the KPIs?	4 What are the KEIs?
 Create / reinforce awareness Generate interest Develop brand preference Increase share of prescription Increase compliance Limit substitution rate Get the brand listed Fine-tune the profile of the customer 	 Physicians (e.g. KOLs, specialists, GPs) Pharmacists (e.g. retail or hospital) Patients Nurses Influencers (e.g. health authorities, "politics", patient advocacy groups, public health insurance, private health insurance, professional associations) 	 Brand Preference Mix index Preference Ladder step Key message memorization rate Share of prescription Sales evolution Change in the number of treatment initiations Profit evolution in € % of hospitals having listed the brand Return on investment 	 % of the target covered by the action % of the target exposed to the action % of the target impacted by the action % of the target having a positive opinion of the action (interest, utility, practicality, quality of execution) Implementation time required vs. planned Actual vs. budgeted cost

Source: Smart Pharma Consulting analysis

¹ Key Performance Indicators – ² Key Execution Indicators

All tactics (actions) should contribute directly or indirectly to enhance the brand perception, the perceived benefits of the services and the corporate reputation

The Customer Brand Preference Tactics

Customer segment #1	Customer segment #2	Customer segment #3
Strategic preference drivers	Strategic preference drivers	Strategic preference drivers
Brand perception	Brand perception	Brand perception
Service quality	Service quality	Service quality
Corporate reputation	Corporate reputation	Corporate reputation

Targeted customers	Objective	Tactic / Action	Timing	Responsible	Budget (K€)	KPIs ¹	KEIs ²

Source: Smart Pharma Consulting analysis

¹ Key Performance Indicators – ² Key Execution Indicators

It is key to make sure – with the help of specific tools – that existing or planned activities will significantly contribute to reinforce the Brand Preference Mix

Examples of pre- or post- assessment tools for tactics

Description			Objective				Targe (HCPs, pa	e t tients)									
Pe	erceive	d valu	e by the target		Excl	usivity		Link to t	he product								
Evaluati	on*		Rationale	Evalua	tion	Rationale	Evaluati	on**	Rationale								
nterest	1 2 <mark>3</mark> 4	5		Total													
Jsefulness	1 2 <mark>3</mark> 4	5					Magnitude	f – M - F									
Convenience	1 2 <mark>3</mark> 4	5		Partial													
Execution	1 2 <mark>3</mark> 4	5		None			Sustainability	f – M - F			A prior	i ass	ses	sment	iool		
ſotal	1 2 <mark>3</mark> 4	5		None													
Impact o prefer	n branc ence		Rationale			Solutions Initiatives	to reinforce to	be prefere E	ntial po valuatio		Objective				Targ (HCPs, p	et atients)	
High					1				Ex	pected v	alue by the target		Exclu	ısivity	Ex	pected li	nk to the product
Moderate		\checkmark			2				Evaluatio	n*	Rationale	Evaluat	ion	Rationale	Evalua	ion**	Rationale
			_	-	-				Interest	12 3 45		Total					
Low				:	3				Usefulness	12 3 45					Magnitude	f – M -	F
None					4				Convenience	12 3 45		Partial	\checkmark				-
									Execution	12 3 45		None			Sustainabilit	/ f – M -	F
									Total	12 3 45		None					
									Barriers		Rationale		KP	Is on brand pr	eference		GO / No GO
									Technical							Yes	
									Regulatory / Legal	•						No	
									Economic							?	

A posteriori assessment tool

6 Recommendations to develop a "Must-Have" Customer Brand Preference Plan

- Design brand plans to help affiliates optimize brands market shares and not only as a formality to be reported at corporate level
- 2. Seek customer preference rather than customer loyalty by improving customers perception of the brand attributes, the quality of the proposed services and the corporate reputation
- Adopt a 4Ws (What? Why? so What? – What to do?) approach to improve the relevance, the consistency and the robustness of the brand plans

- 4. Use the "Advanced SWOT" to facilitate the analysis of the market situation and of the brand competitive position, identifying market opportunities and threats and prioritizing brand strengths and weaknesses
- Make the best use of the "Customer Brand Preference Card" to formalize clearly and precisely the brand ambition, the strategic preference drivers by customer segment and the corresponding key tactics
- 6. Define Key Execution Indicators and Key Performance Indicators to monitor respectively the quality of execution and the impact of the actions

Smart Pharma Consulting Expertise in Strategic Planning Process

- Over the past 15 years, we have contributed to the development of ~70 brand plans for 32 pharma companies in 16 therapeutic areas:
 - 1. Allergy

9. Nephrology
 10. Neurology

12. Oncology

14. Psychiatry

11. Ophthalmology

- 2. Cardiology
- 3. Dermatology
- 4. Gastroenterology
- 5. Gynecology
- 6. Hematology
- 7. Infectiology / Virology
- 8. Metabolism / Diabetes
- 15. Rheumatology

13. Pulmonology

- 16. Urology
- Providing robust methodologies and tools
- Positively challenging brand teams analyses and recommendations
- Facilitating strategic thinking seminars, with multidisciplinary brand teams...
- ... in multi-national environments: Europe, North and Latin America, Middle-East and Asia

- Smart Pharma Consulting will help your brand teams address the following key issues:
 - 1. Which market analyses should be carried out?
 - 2. How to define market key success factors and the corresponding brand challenges with the help of the "Advanced SWOT"?
 - 3. How to develop market and brand scenarios?
 - 4. How to define the brand performance ambition?
 - 5. How to craft a Customer Brand Preference strategy per customer segment to achieve this ambition?
 - 6. How to support the strategy by tactical initiatives likely to reinforce the Brand Preference Mix?
 - 7. How to anticipate the impact of future investment options on the brand performance?
 - 8. How to monitor the quality of execution and the impact of investment decisions?



Consulting company dedicated to Strategy, Management and Organization services in the pharmaceutical sector

